FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982202083> ?p ?o ?g. }

• W2982202083 abstract "Abstract Background Data are limited about the burden of respiratory syncytial virus (RSV)-related hospitalizations in older adults and those with COPD or CHF. Methods We conducted prospective surveillance at two hospitals from October 2018 to March 2019 for adults ≥50 years of age admitted with acute respiratory infections (ARI) and adults of any age with COPD or CHF-related admissions. Adults were eligible if they were residents of an 8 county region in Atlanta, Georgia. Asymptomatic adults ≥50 years of age were enrolled as controls. Nasopharyngeal and oropharyngeal swabs were tested for RSV and influenza (Flu) using BioFire® FilmArray® Respiratory Viral Panel (RVP) and acute/convalescent serology was obtained for RSV antibodies detection by enzyme immunoassay against RSV lysate. Standard of care results were included for enrollees. We compare the number of RSV+, Flu+ and RSV−/Flu− cases along with demographic features and outcomes. Results We screened 12,453 patients to identify 1,515 eligible adults of which 617 (41%) were enrolled. The most common reasons for failing to enroll were refusal (676, 75%) and inability to obtain informed consent (221, 25%). Of the 617, 36 (6%) were RSV+ and 41 (7%) were Flu+. RSV was detected in 1/126 (0.8%) and Flu in 0/126 healthy controls. RSV+ occurred earlier in surveillance and peaked at a higher frequency (figure). Clinical characteristics and outcomes are in the table. In a convenience sample, a four-fold rise in RSV antibody titer was detected among 8/15 RSV+, 0/42 RSV−/Flu−, and 0/42 healthy controls. Conclusion The burden and outcomes for RSV are similar to Flu in adults admitted to the hospital with ARI, CHF, or COPD. A vaccine for RSV would be beneficial. Disclosures Nadine Rouphael, MD, Merck: I conduct as Emory PI the PNEUMO MERCK study at Emory, Research Grant; Pfizer: I conduct as co-PI the RSV PFIZER study at Emory, Research Grant; Sanofi-Pasteur: I conducted as Emory PI the CDIFFENSE trial at Emory, Research Grant." @default.
• W2982202083 created "2019-11-01" @default.
• W2982202083 creator A5001923727 @default.
• W2982202083 creator A5002033847 @default.
• W2982202083 creator A5002831294 @default.
• W2982202083 creator A5003982745 @default.
• W2982202083 creator A5006730306 @default.
• W2982202083 creator A5008239744 @default.
• W2982202083 creator A5010118231 @default.
• W2982202083 creator A5010725830 @default.
• W2982202083 creator A5012004721 @default.
• W2982202083 creator A5012184170 @default.
• W2982202083 creator A5017740070 @default.
• W2982202083 creator A5018571002 @default.
• W2982202083 creator A5019481403 @default.
• W2982202083 creator A5022646071 @default.
• W2982202083 creator A5024530617 @default.
• W2982202083 creator A5026664731 @default.
• W2982202083 creator A5028057418 @default.
• W2982202083 creator A5028948639 @default.
• W2982202083 creator A5029649129 @default.
• W2982202083 creator A5037742092 @default.
• W2982202083 creator A5038127443 @default.
• W2982202083 creator A5040670236 @default.
• W2982202083 creator A5041183761 @default.
• W2982202083 creator A5042720182 @default.
• W2982202083 creator A5044428463 @default.
• W2982202083 creator A5044731926 @default.
• W2982202083 creator A5046812477 @default.
• W2982202083 creator A5046895922 @default.
• W2982202083 creator A5050186673 @default.
• W2982202083 creator A5051527548 @default.
• W2982202083 creator A5052029724 @default.
• W2982202083 creator A5053472373 @default.
• W2982202083 creator A5053600656 @default.
• W2982202083 creator A5057537741 @default.
• W2982202083 creator A5058017922 @default.
• W2982202083 creator A5058375372 @default.
• W2982202083 creator A5061664283 @default.
• W2982202083 creator A5074893397 @default.
• W2982202083 creator A5075601943 @default.
• W2982202083 creator A5075978935 @default.
• W2982202083 creator A5077183317 @default.
• W2982202083 creator A5078498247 @default.
• W2982202083 creator A5079489250 @default.
• W2982202083 creator A5081122395 @default.
• W2982202083 creator A5083052414 @default.
• W2982202083 creator A5083072135 @default.
• W2982202083 creator A5087553786 @default.
• W2982202083 date "2019-10-01" @default.
• W2982202083 modified "2023-10-07" @default.
• W2982202083 title "2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)" @default.
• W2982202083 doi "https://doi.org/10.1093/ofid/ofz360.1992" @default.
• W2982202083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6810302" @default.
• W2982202083 hasPublicationYear "2019" @default.
• W2982202083 type Work @default.
• W2982202083 sameAs 2982202083 @default.
• W2982202083 citedByCount "0" @default.
• W2982202083 crossrefType "journal-article" @default.
• W2982202083 hasAuthorship W2982202083A5001923727 @default.
• W2982202083 hasAuthorship W2982202083A5002033847 @default.
• W2982202083 hasAuthorship W2982202083A5002831294 @default.
• W2982202083 hasAuthorship W2982202083A5003982745 @default.
• W2982202083 hasAuthorship W2982202083A5006730306 @default.
• W2982202083 hasAuthorship W2982202083A5008239744 @default.
• W2982202083 hasAuthorship W2982202083A5010118231 @default.
• W2982202083 hasAuthorship W2982202083A5010725830 @default.
• W2982202083 hasAuthorship W2982202083A5012004721 @default.
• W2982202083 hasAuthorship W2982202083A5012184170 @default.
• W2982202083 hasAuthorship W2982202083A5017740070 @default.
• W2982202083 hasAuthorship W2982202083A5018571002 @default.
• W2982202083 hasAuthorship W2982202083A5019481403 @default.
• W2982202083 hasAuthorship W2982202083A5022646071 @default.
• W2982202083 hasAuthorship W2982202083A5024530617 @default.
• W2982202083 hasAuthorship W2982202083A5026664731 @default.
• W2982202083 hasAuthorship W2982202083A5028057418 @default.
• W2982202083 hasAuthorship W2982202083A5028948639 @default.
• W2982202083 hasAuthorship W2982202083A5029649129 @default.
• W2982202083 hasAuthorship W2982202083A5037742092 @default.
• W2982202083 hasAuthorship W2982202083A5038127443 @default.
• W2982202083 hasAuthorship W2982202083A5040670236 @default.
• W2982202083 hasAuthorship W2982202083A5041183761 @default.
• W2982202083 hasAuthorship W2982202083A5042720182 @default.
• W2982202083 hasAuthorship W2982202083A5044428463 @default.
• W2982202083 hasAuthorship W2982202083A5044731926 @default.
• W2982202083 hasAuthorship W2982202083A5046812477 @default.
• W2982202083 hasAuthorship W2982202083A5046895922 @default.
• W2982202083 hasAuthorship W2982202083A5050186673 @default.
• W2982202083 hasAuthorship W2982202083A5051527548 @default.
• W2982202083 hasAuthorship W2982202083A5052029724 @default.
• W2982202083 hasAuthorship W2982202083A5053472373 @default.
• W2982202083 hasAuthorship W2982202083A5053600656 @default.
• W2982202083 hasAuthorship W2982202083A5057537741 @default.
• W2982202083 hasAuthorship W2982202083A5058017922 @default.
• W2982202083 hasAuthorship W2982202083A5058375372 @default.
• W2982202083 hasAuthorship W2982202083A5061664283 @default.
• W2982202083 hasAuthorship W2982202083A5074893397 @default.
• W2982202083 hasAuthorship W2982202083A5075601943 @default.
• W2982202083 hasAuthorship W2982202083A5075978935 @default.
• W2982202083 hasAuthorship W2982202083A5077183317 @default.

• next